[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ISISPHARMA\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100633036",false,"NCT07521462","Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy","Impact of Using a Dermocosmetic Product as Monotherapy or as an Adjunct to Laser Treatment on Redness Associated With Erythematotelangiectatic Rosacea: a Comparative Study Versus Placebo.","Inclusion Criteria:\n\n* Gender: male or female\n* Age: \\> 18 years -Patients with mild to severe erythro-couperotic rosacea (stage 2, 3, or 4 - TRoSA scale, section 2.2.3.1)\n* Patients wishing to undergo vascular laser treatments for their rosacea\n* Patients who have provided informed consent\n\nExclusion Criteria:\n\n* Pregnant patients or patients with a positive urine pregnancy test at the initial visit\n* Patients with another condition in the study area.\n* Patients who have received laser treatment for the same condition within the previous 12 months.\n* Patients with another form of rosacea (e.g., papules and pustules, ocular rosacea, etc.).\n* Patients using another anti-redness product on the face during the study.\n* Patients who have taken photosensitizing treatments during the month prior to study enrollment.\n* Patients taking or having taken oral isotretinoin within 6 months prior to study enrollment.\n* Patients enrolled in another study.\n* Adult patients under a legal guardianship arrangement (guardianship, conservatorship, judicial protection).\n* Patients not covered by social security.","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","The aim of this clinical study is to evaluate the effectiveness and safety of a dermocosmetic product in reducing facial redness and visible blood vessels associated with erythematotelangiectatic rosacea.\n\nInvestigators will compare the dermocosmetic product to a placebo applied to opposite sides of the face, when used alone and in combination with laser treatment.\n\nParticipants will apply the products twice daily for 2 month followed by continued use in combination with laser treatment, and will attend regular clinical visits for assessments and questionnaires.",[25,26],"Rosacea, Erythematotelangiectatic","Rosacea Subtype 1 (Erythematotelangiectatic)",[28,29,30,31],"Erythematotelangiectatic Rosacea","Telangiectasia","Dermocosmetic","Laser Therapy","NOT_YET_RECRUITING","2026-04-03",{"date":35,"type":36},"2026-04-13","ACTUAL",{"date":38,"type":19},"2026-09-01",{"date":40,"type":19},"2027-06-30",{"name":42,"class":43},"ISISPHARMA","INDUSTRY",""]